PERSISTENCE, COMPLIANCE AND BISPHOSPHONATE SWITCHING IN PATIENTS WITH MULTIPLE MYELOMA (MM) IN GERMANY

被引：0
|
作者：
Intorcia, M. [1 ]
Ansorge, S. [2 ]
Giannopoulou, C. [1 ]
Hohmann, D. [3 ]
机构：
[1] Amgen GmbH, Zug, Switzerland
[2] Arvato Hlth Analyt, Munich, Germany
[3] Amgen GmbH, Munich, Germany
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.367
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN284
引用
收藏
页码：A463 / A463
页数：1
相关论文
共 50 条
  • [1] Bisphosphonate use in multiple myeloma: an audit of compliance and cost analysis
    Farrugia, Daniel
    Sultana, Erika
    Gauci, Luca
    Cutajar, Maria
    Micallef, Francesca
    Gatt, Alexander
    Camilleri, David James
    Grech, Mark
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 178 - 178
  • [2] Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)
    Badros, Ashraf
    Philip, Sunita
    Lesho, Patricia
    Sadowska, Mariola
    Weikel, Dianna
    Meiller, Timothy
    Lapidus, Rena
    Hester, Lisa
    Milliron, Todd
    Goloubeva, Olga
    BLOOD, 2013, 122 (21)
  • [3] Oral bisphosphonate compliance and persistence: a matter of choice?
    Silverman, S. L.
    Schousboe, J. T.
    Gold, D. T.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (01) : 21 - 26
  • [4] Improving compliance and persistence with bisphosphonate therapy for osteoporosis
    Emkey, RD
    Ettinger, M
    AMERICAN JOURNAL OF MEDICINE, 2006, 119 (04): : 18S - 24S
  • [5] Oral bisphosphonate compliance and persistence: a matter of choice?
    S. L. Silverman
    J. T. Schousboe
    D. T. Gold
    Osteoporosis International, 2011, 22 : 21 - 26
  • [6] Bisphosphonate treatment for multiple myeloma
    Terpos, E
    Rahemtulla, A
    DRUGS OF TODAY, 2004, 40 (01): : 29 - 40
  • [7] Bisphosphonate therapy in multiple myeloma
    Laakso, M
    Jantunen, E
    ACTA ONCOLOGICA, 1996, 35 (05) : 55 - 56
  • [8] SWITCHING FROM BRANDED ALENDRONATE OR RISEDRONATE TO GENERIC ALENDRONATE: EFFECT ON PERSISTENCE WITH BISPHOSPHONATE THERAPY IN GERMANY
    Ziller, V.
    Schuessel, K.
    Czeche, S.
    Franzmann, A.
    Kloeckner, D.
    Quinzler, R.
    Schulz, M.
    Moehrke, W.
    Hadji, P.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 112 - 112
  • [9] Switching from branded alendronate or risedronate to generic alendronate: Effect on persistence with bisphosphonate therapy in Germany
    Ziller, V.
    Schuessel, K.
    Czeche, S.
    Franzmann, A.
    Kloeckner, D.
    Quinzler, R.
    Schulz, M.
    Moehrke, W.
    Hadji, P.
    BONE, 2009, 44 (02) : S449 - S450
  • [10] Health-Related Quality of Life (HRQOL) Reported by Patients with Multiple Myeloma (MM) in Germany
    Engelhardt, Monika
    Ihorst, Gabriele
    Singh, Moushmi
    Schoehl, Martina
    Rieth, Achim
    Saba, Grece
    Pellan, Marine
    Lebioda, Andrea
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 157 - 157
12345